Elevation Oncology Files 8-K with Major Corporate Changes
| Field | Detail |
|---|---|
| Company | Elevation Oncology, Inc. |
| Form Type | 8-K |
| Filed Date | Jul 23, 2025 |
| Risk Level | high |
| Sentiment | mixed |
Sentiment: mixed
Topics: acquisition-disposition, listing-rule, change-of-control, corporate-governance
TL;DR
Elevation Oncology's 8-K signals major corporate events: asset changes, potential delisting, and leadership shifts.
AI Summary
On July 23, 2025, Elevation Oncology, Inc. filed an 8-K detailing several significant events. These include the completion of an acquisition or disposition of assets, a notice of potential delisting or failure to meet listing standards, material modifications to security holder rights, and changes in control of the registrant. The filing also addresses departures and elections of directors and officers, compensatory arrangements, and amendments to articles of incorporation or bylaws.
Why It Matters
This 8-K filing indicates significant structural and operational shifts for Elevation Oncology, potentially impacting its stock listing, governance, and asset base.
Risk Assessment
Risk Level: high — The filing mentions potential delisting and changes in control, which are significant risk factors for investors.
Key Players & Entities
- Elevation Oncology, Inc. (company) — Registrant
- July 23, 2025 (date) — Date of earliest event reported
- 101 Federal Street, Suite 1900, Boston, MA 02110 (address) — Business and Mail Address
- 14ner Oncology, Inc. (company) — Former Company Name
- NASDAQ (company) — Listing Exchange
FAQ
What specific assets were acquired or disposed of by Elevation Oncology?
The filing does not specify the details of the asset acquisition or disposition, only that it occurred.
What are the reasons for the notice of delisting or failure to satisfy listing rules?
The filing indicates a notice of delisting or failure to satisfy a continued listing rule or standard, but the specific reasons are not detailed in this summary.
What material modifications have been made to the rights of security holders?
The filing states there were material modifications to the rights of security holders, but the nature of these modifications is not specified.
What change in control has occurred at Elevation Oncology?
The filing reports a change in control of the registrant, but the specifics of this change are not provided.
Are there any new compensatory arrangements for officers mentioned in this filing?
The filing mentions compensatory arrangements of certain officers as an item of disclosure, but the details of these arrangements are not included in the provided text.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 23, 2025 regarding Elevation Oncology, Inc..